Evidence map›Paper›PMID 40125024›Full record

ReviewNuclear medicine and molecular imaging2025

Production and Supply of Raw Materials for Radiometals used in Radionuclide Imaging and Therapy in Korea.

Seok-Jun Seo, Youngho Seo

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Seok-Jun SeoKorea National Institute of Rare Metals, Korea Institute of Industrial Technology, Incheon, Republic of Korea.ORCID 0000-0001-7599-743X
Youngho SeoDepartment of Radiology and Biomedical Imaging, University of California, San Francisco, CA USA.ORCID 0000-0001-5908-6636

Funding

Energy-independent single photon molecular imaging technologyR01EB026331 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CUI, YONGGANG, SEO, YOUNGHO · 2018 to 2022
$2.6M
NIBIB NIH HHS R01 EB026331
6 · The paper itself

Abstract

Radiometals, with their favorable decay properties and rich coordination chemistry, have found widespread applications in both diagnostic and therapeutic nuclear medicine. To ensure effective utilization, radiometal-based radiopharmaceuticals are designed to target specific organs or cells. Radiometals are primarily produced in cyclotrons or reactors using stable isotopes as raw materials. Many countries, including Korea, are pursuing self-sufficiency in radiometal production at the government level. This review examines the current production and supply status of raw materials for key radiometals that are either actively used or expected to see a significant demand growth in the future in Korea. Graphical Abstract: Flow of radiometal production.

Indexed as

Nuclear medicineProductionRadiometalRaw materialsSupplyTheranostics

Identifiers

PMID40125024
PMCPMC11923314

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.